Sabrina R.
- Country
- Italy
- Department
- Medical Oncology
Research Overview
- Phase II Study of Inavolisib and Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
- Phase III Randomized Trial of Docetaxel plus Apalutamide Intensification in Metastatic Hormone-Sensitive Prostate Cancer with Inadequate PSA Response
- Phase II Study of Lutetium (177Lu) Vipivotide Tetraxetan with Androgen Receptor Pathway Inhibitors in PSMA PET Positive Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 150 of 365 partner sites.
Specializations
Advanced Prostate Cancer Management
This investigator specializes in treating metastatic castration-resistant prostate cancer (mCRPC), with particular focus on novel therapeutic approaches and combination treatments.
- PSMA-targeted therapies
- Androgen receptor pathway inhibitors
- Novel hormonal therapy optimization
Their research encompasses treatment strategies for patients with varying disease stages and complications.
Precision Oncology Applications
The investigator focuses on molecular imaging-guided treatment approaches, particularly utilizing PSMA PET scanning for targeted therapy selection and monitoring.
- Biomarker-driven treatment selection
- Radiopharmaceutical therapeutics
- Treatment response assessment
Their work integrates advanced imaging techniques with therapeutic decision-making.
Special Patient Populations
The investigator addresses specific needs of distinct patient groups, including those with biochemically recurrent prostate cancer and patients with concurrent medical conditions.
- Frail patient management
- Renal function considerations
- Early-stage intervention strategies
Their research encompasses tailored therapeutic approaches for varying patient profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.